| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
35,184 |
30,197 |
$2.01M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
8,625 |
8,579 |
$575K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
13,177 |
11,531 |
$431K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,420 |
10,922 |
$310K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,994 |
1,823 |
$99K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,325 |
1,250 |
$93K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,501 |
3,163 |
$71K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
708 |
708 |
$39K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
411 |
410 |
$38K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,477 |
3,272 |
$38K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,621 |
3,170 |
$29K |
| S9083 |
Global fee urgent care centers |
822 |
676 |
$19K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,068 |
2,027 |
$18K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
375 |
367 |
$13K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,327 |
1,216 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
225 |
220 |
$6K |
| 87428 |
|
144 |
143 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
200 |
192 |
$3K |
| 99195 |
|
59 |
55 |
$3K |
| 93923 |
|
37 |
34 |
$3K |
| 99201 |
|
78 |
78 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
936 |
890 |
$3K |
| 95923 |
|
33 |
31 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,569 |
1,417 |
$2K |
| 81001 |
|
1,147 |
1,100 |
$1K |
| 95921 |
|
29 |
28 |
$1K |
| 99072 |
|
3,499 |
3,103 |
$1K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
47 |
46 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
44 |
44 |
$871.50 |
| 87420 |
|
169 |
168 |
$852.48 |
| 99001 |
|
986 |
940 |
$820.72 |
| 81025 |
|
61 |
56 |
$377.94 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
691 |
654 |
$363.74 |
| 0011A |
|
12 |
12 |
$264.95 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
184 |
128 |
$253.73 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
186 |
163 |
$243.66 |
| 93040 |
|
29 |
28 |
$188.06 |
| 99000 |
|
121 |
115 |
$180.70 |
| 73130 |
|
13 |
12 |
$167.02 |
| 81002 |
|
47 |
44 |
$118.31 |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
2,547 |
2,442 |
$111.25 |
| 90715 |
|
14 |
13 |
$73.53 |
| 81005 |
|
41 |
40 |
$32.36 |
| G0403 |
Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report |
14 |
13 |
$11.49 |
| 3011F |
|
13 |
12 |
$0.04 |
| 90658 |
|
16 |
16 |
$0.02 |
| 90461 |
|
14 |
13 |
$0.00 |